The investment landscape for orthopedic innovation is shifting under our feet, and to get a clear view of the damage, we’re looking at two recent, sobering deep dives from J.P. Morgan’s equity research team.
The first, "What’s Troubling SMid Cap MedTech?" (February 12, 2026), outlines why small and mid-cap stocks have fallen so far out of favor that they are now trading at trough multiples not seen since the Great Financial Crisis.
The follow-up report, "Enough Is Enough; Valuation Compression Appears to Have Gone Too Far" (March 12, 2026), argues that while the "AI trade" has sucked the oxy...
